Annals of the New York Academy of SciencesVolume 698, Issue 1 p. 318-328 Endocrine Therapy of Breast Cancer The Experience of the Italian Cooperative Group for Chemohormonal Therapy of Early Breast Cancer (GROCTA) FRANCESCO BOCCARDO, Corresponding Author FRANCESCO BOCCARDO Div. di Oncologia Medica II, Istituto Nazionale per la Ricerca sul Cancro, Viale Benedetto XV, 10, 16132 Genova, Italy.Francesco Boccardo, M.D., Div. di Oncologia Medica II, Istituto Nazionale per la Ricerca sul Cancro, Viale Benedetto XV, 10, 16132 Genova, Italy.Search for more papers by this authorDOMENICO AMOROSO, DOMENICO AMOROSO Div. di Oncologia Medica II, Istituto Nazionale per la Ricerca sul Cancro, Viale Benedetto XV, 10, 16132 Genova, Italy.Search for more papers by this authorALESSANDRA RUBAGOTTI, ALESSANDRA RUBAGOTTI Div. di Oncologia Medica II, Istituto Nazionale per la Ricerca sul Cancro, Viale Benedetto XV, 10, 16132 Genova, Italy.Search for more papers by this authorPIERO SISMONDI, PIERO SISMONDI Cattedra di Ginecologja Oncologica, Università di Torino, Italy.Search for more papers by this authorCORRADO DE SANCTIS, CORRADO DE SANCTIS Cattedra di Ginecologja Oncologica, Università di Torino, Italy.Search for more papers by this authorMARIO CAPPELLINI, MARIO CAPPELLINI Unità Operativa Radioterapia, Policlinico Careggi, Firenze, Italy.Search for more papers by this authorPAOLO PACINI, PAOLO PACINI Unità Operativa Radioterapia, Policlinico Careggi, Firenze, Italy.Search for more papers by this authorLUIGI CASTAGNETTA, LUIGI CASTAGNETTA Biochimica degli Ormoni, Università di Palermo, Italy.Search for more papers by this authorADELE TRAINA, ADELE TRAINA Biochimica degli Ormoni, Università di Palermo, Italy.Search for more papers by this authorANTONIO FARRIS, ANTONIO FARRIS Cattedra di Oncologia Clinica, Università di Sassari, Italy.Search for more papers by this authorSTEFANO IACOBELLI, STEFANO IACOBELLI Cattedra di Oncologia Medica, Università di Chieti, Italy.Search for more papers by this authorGIORGIO MUSTACCHI, GIORGIO MUSTACCHI Centra Oncologico, Trieste, Italy.Search for more papers by this authorITALO NENCI, ITALO NENCI Istituto Anatomia Patologica, Università di Ferrara, Italy.Search for more papers by this authorADRIANO PIFFANELLI, ADRIANO PIFFANELLI Istituto di Radiologia, Università di Ferrara, Italy.Search for more papers by this authorEUGENIO VILLA, EUGENIO VILLA Radio-Chemioterapia, Istituto Scientifico S. Raflaele, Milano, Italy.Search for more papers by this authorDANIELA ALDRIGHETTI, DANIELA ALDRIGHETTI Radio-Chemioterapia, Istituto Scientifico S. Raflaele, Milano, Italy.Search for more papers by this authorLUIGI GALLO, LUIGI GALLO Oncologia Medica, Ospedali Galliera, Genova Italy.Search for more papers by this authorMARIO MESITI, MARIO MESITI Cattedra di Oncologia, Università di Messina, Italy.Search for more papers by this authorGIUSEPPE SCHIEPPATI, GIUSEPPE SCHIEPPATI Medicina I, Ospedale Generale Provinciale, Saronno (VA), Italy.Search for more papers by this authorOTHER PARTICIPANTS IN THE GROCTA TRIALS, OTHER PARTICIPANTS IN THE GROCTA TRIALS Div. di Oncologia Medica II, Istituto Nazionale per la Ricerca sul Cancro, Viale Benedetto XV, 10, 16132 Genova, Italy.Search for more papers by this author FRANCESCO BOCCARDO, Corresponding Author FRANCESCO BOCCARDO Div. di Oncologia Medica II, Istituto Nazionale per la Ricerca sul Cancro, Viale Benedetto XV, 10, 16132 Genova, Italy.Francesco Boccardo, M.D., Div. di Oncologia Medica II, Istituto Nazionale per la Ricerca sul Cancro, Viale Benedetto XV, 10, 16132 Genova, Italy.Search for more papers by this authorDOMENICO AMOROSO, DOMENICO AMOROSO Div. di Oncologia Medica II, Istituto Nazionale per la Ricerca sul Cancro, Viale Benedetto XV, 10, 16132 Genova, Italy.Search for more papers by this authorALESSANDRA RUBAGOTTI, ALESSANDRA RUBAGOTTI Div. di Oncologia Medica II, Istituto Nazionale per la Ricerca sul Cancro, Viale Benedetto XV, 10, 16132 Genova, Italy.Search for more papers by this authorPIERO SISMONDI, PIERO SISMONDI Cattedra di Ginecologja Oncologica, Università di Torino, Italy.Search for more papers by this authorCORRADO DE SANCTIS, CORRADO DE SANCTIS Cattedra di Ginecologja Oncologica, Università di Torino, Italy.Search for more papers by this authorMARIO CAPPELLINI, MARIO CAPPELLINI Unità Operativa Radioterapia, Policlinico Careggi, Firenze, Italy.Search for more papers by this authorPAOLO PACINI, PAOLO PACINI Unità Operativa Radioterapia, Policlinico Careggi, Firenze, Italy.Search for more papers by this authorLUIGI CASTAGNETTA, LUIGI CASTAGNETTA Biochimica degli Ormoni, Università di Palermo, Italy.Search for more papers by this authorADELE TRAINA, ADELE TRAINA Biochimica degli Ormoni, Università di Palermo, Italy.Search for more papers by this authorANTONIO FARRIS, ANTONIO FARRIS Cattedra di Oncologia Clinica, Università di Sassari, Italy.Search for more papers by this authorSTEFANO IACOBELLI, STEFANO IACOBELLI Cattedra di Oncologia Medica, Università di Chieti, Italy.Search for more papers by this authorGIORGIO MUSTACCHI, GIORGIO MUSTACCHI Centra Oncologico, Trieste, Italy.Search for more papers by this authorITALO NENCI, ITALO NENCI Istituto Anatomia Patologica, Università di Ferrara, Italy.Search for more papers by this authorADRIANO PIFFANELLI, ADRIANO PIFFANELLI Istituto di Radiologia, Università di Ferrara, Italy.Search for more papers by this authorEUGENIO VILLA, EUGENIO VILLA Radio-Chemioterapia, Istituto Scientifico S. Raflaele, Milano, Italy.Search for more papers by this authorDANIELA ALDRIGHETTI, DANIELA ALDRIGHETTI Radio-Chemioterapia, Istituto Scientifico S. Raflaele, Milano, Italy.Search for more papers by this authorLUIGI GALLO, LUIGI GALLO Oncologia Medica, Ospedali Galliera, Genova Italy.Search for more papers by this authorMARIO MESITI, MARIO MESITI Cattedra di Oncologia, Università di Messina, Italy.Search for more papers by this authorGIUSEPPE SCHIEPPATI, GIUSEPPE SCHIEPPATI Medicina I, Ospedale Generale Provinciale, Saronno (VA), Italy.Search for more papers by this authorOTHER PARTICIPANTS IN THE GROCTA TRIALS, OTHER PARTICIPANTS IN THE GROCTA TRIALS Div. di Oncologia Medica II, Istituto Nazionale per la Ricerca sul Cancro, Viale Benedetto XV, 10, 16132 Genova, Italy.Search for more papers by this author First published: November 1993 https://doi.org/10.1111/j.1749-6632.1993.tb17222.xCitations: 7 See Appendix. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Citing Literature Volume698, Issue1Breast Cancer: From Biology to Therapy–Pisa Symposia in OncologyNovember 1993Pages 318-328 RelatedInformation

The aim of the present study is to confirm the antitumor activity of orally administered idarubicin (IDA) in patients with advanced breast cancer. Doxorubicin (ADRIA) was chosen as control treatment and the patients were randomized to receive either IDA or ADRIA according to a 2:1 ratio. Sixty-three patients, 77% of whom were pretreated with chemotherapy excluding anthracyclines, entered the study. The doses were: IDA 45 mg/m2 orally on 3 consecutive days every 28 days: ADRIA 75 (60) mg/m2 intravenously every 21 days. A complete + partial response (CR + PR) was observed in 11/37 (30%) evaluable cases treated with IDA and in 6/19 (32%) cases treated with ADRIA. If all the patients were included, the CR + PR remission rates were 27.5 and 27%, respectively. There were no significant differences as regards time to remission, duration of remission and survival. None of 10 cases who crossed over the treatments responded to the second therapy. The most frequent side effects of IDA were myelosuppression and nausea/vomiting. The only significant statistical difference between the two anthracyclines was the lower incidence of alopecia after IDA. Although there were 3 cases of cardiotoxicity after ADRIA, 2 of which severe, no case of clinical cardiotoxicity was observed after IDA. The present study confirms that orally administered IDA is an active agent in advanced breast cancer.

Annals of the New York Academy of SciencesVolume 464, Issue 1 p. 611-612 The Treatment of Benign Breast Disease: Comparison of Bromocriptine, Norethisterone Acetate, and Placebo F. SACCANI, F. SACCANI Divisione di Oncologia Arcispedale S. Maria Nueva Reggio Emilia, ItalySearch for more papers by this authorG. BECCHI, G. BECCHI Divisione di Oncologia Arcispedale S. Maria Nueva Reggio Emilia, ItalySearch for more papers by this authorM. SASSI, M. SASSI Divisione di Oncologia Arcispedale S. Maria Nueva Reggio Emilia, ItalySearch for more papers by this authorA. ZADRO, A. ZADRO Divisione di Oncologia Arcispedale S. Maria Nueva Reggio Emilia, ItalySearch for more papers by this authorG. SACCANI JOTTI, G. SACCANI JOTTI Istituto di Anatomïa Patologica Università degli Studi di Parma Parma, ItalySearch for more papers by this author F. SACCANI, F. SACCANI Divisione di Oncologia Arcispedale S. Maria Nueva Reggio Emilia, ItalySearch for more papers by this authorG. BECCHI, G. BECCHI Divisione di Oncologia Arcispedale S. Maria Nueva Reggio Emilia, ItalySearch for more papers by this authorM. SASSI, M. SASSI Divisione di Oncologia Arcispedale S. Maria Nueva Reggio Emilia, ItalySearch for more papers by this authorA. ZADRO, A. ZADRO Divisione di Oncologia Arcispedale S. Maria Nueva Reggio Emilia, ItalySearch for more papers by this authorG. SACCANI JOTTI, G. SACCANI JOTTI Istituto di Anatomïa Patologica Università degli Studi di Parma Parma, ItalySearch for more papers by this author First published: June 1986 https://doi.org/10.1111/j.1749-6632.1986.tb16085.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume464, Issue1Endocrinology of the Breast: Basic and Clinical AspectsJune 1986Pages 611-612 RelatedInformation

High dose MAP (medroxyprogesterone acetate) and TAM (tamoxifen) were administered orally to 31 postmenopausal patients with advanced breast cancer. CR (complete remission) was achieved in 1 (3%) and PR (partial remission) in 11 (32%) patients for a median duration of 12 months. The treatment was well tolerated and in no instance was interrupted because of toxicity. This study does not support the hypothesis that the combination of MAP and TAM gives better results than the single agents.

The clinical applications of the radioimmunoassay evaluation of the carcinoembryonic antigen (CEA) are examined here, with special reference to the follow-up of patients undertaking radiotherapy for uterus cancers, portio and bladder cancers, whether after surgery of not. In addition the Authors point out the levels of negativity for every test method, so that the possible crossed reaction with CEA-like substances can be taken into account.

We have demonstrated the possibility of administering MAP (i.m.) at much higher doses than was ever previously employed. Daily dosage of 1500 mg i.m. of MAP for 30 consecutive days was an effective (44% CR + PR) and well tolerated treatment for advanced breast cancer. The aim of the present prospective and randomized study was to compare the above regimen with a daily dose of 500 mg i.m. for 30 days in postmenopausal women with metastatic breast cancer. A hundred patients were admitted to the study and 46 in each group were evaluable; the groups were similar for age, duration of the disease, time from menopause, performance status, dominant metastatic lesion and previous therapy, 2146 (45.7%) patients in the 1500 group and 2046 (43.5%) patients in the 500 group showed major objective responses (CR + PR). The incidence of minimal response, no change and progression was 13, 15.2 and 26.1% respectively in the 1500 mg group and 2.2, 15.2 and 39.1% in the 500 mg group. When all kinds of responses as well as the incidence of progression are taken into consideration the activity of the 1500 mg regimen was significantly superior. Bone metastasis gave the best response in both groups (65 and 56% respectively). Mean remission duration for CR + PR was 6 + months in both groups.